Clinical trial NCT01525615 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion criteria:

          1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to
             participation in the trial, which includes medication washout and restrictions.

          2. All patients must have a diagnosis of chronic obstructive pulmonary disease and must
             meet the following spirometric criteria:

             Patients must have relatively stable airway obstruction with, at visit 1:

             a post-bronchodilator 30% <= FEV1 <80% of predicted normal (ECSC) and a
             post-bronchodilator FEV1/FVC <70% at Visit 1

          3. Male or female patients, between 40 and 75 years (inclusive) of age on day of signing
             informed consent.

          4. Patients must be current or ex-smokers with a smoking history of more than 10 pack
             years Patients who have never smoked cigarettes must be excluded.

          5. Patients must be able to perform technically acceptable pulmonary function tests
             (spirometry), must be able to complete multiple symptom-limited cycle ergometry tests
             (and for a subset also shuttle walk tests), as required in the protocol.

          6. Patients must be able to inhale medication in a competent manner from the RESPIMAT
             inhaler and from a metered dose inhaler (MDI).

        Exclusion criteria:

          1. Patients with a significant disease other than COPD

          2. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or
             urinalysis; all patients with an SGOT > x2 ULN, SGPT > x2 ULN, bilirubin > x2 ULN or
             creatinine > x2 ULN will be excluded regardless of clinical condition

          3. Patients with a history of asthma

          4. A diagnosis of thyrotoxicosis

          5. A diagnosis of paroxysmal tachycardia (>100 beats per minute)

          6. A history of myocardial infarction within 1 year of screening visit (Visit 1)

          7. Unstable or life-threatening cardiac arrhythmia

          8. Hospitalized for heart failure within the past year

          9. Known active tuberculosis

         10. A malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

         11. A history of life-threatening pulmonary obstruction and patients with chronic
             respiratory failure

         12. A history of cystic fibrosis

         13. Clinically evident bronchiectasis

         14. A history of significant alcohol or drug abuse

         15. Any contraindications for exercise testing

         16. Patients who have undergone thoracotomy with pulmonary resection

         17. Patients being treated with any oral ß-adrenergics

         18. Patients being treated with oral corticosteroid medication at unstable doses (i.e.,
             less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg
             of prednisone per day or 20 mg every other day

         19. Patients who regularly use daytime oxygen therapy for more than one hour per day and
             in the investigator's opinion will be unable to abstain from the use of oxygen therapy
             during clinic visits

         20. Patients who have completed a pulmonary rehabilitation program in the six weeks prior
             to the screening visit (Visit 1) or patients who are currently in a pulmonary
             rehabilitation program

         21. Patients who have a limitation of exercise performance as a result of factors other
             than fatigue or exertional dyspnoea or morbid obesity

         22. Patients with an endurance time >=25 minutes during the training (Visit 2) or baseline
             (Visit 3) constant work rate cycle ergometry

         23. Patients who have taken an investigational drug within one month or six half lives
             (whichever is greater) prior to screening visit (Visit 1)

         24. Patients with known hypersensitivity to ß-adrenergic drugs, anticholinergic drugs,
             BAC, EDTA or any other component of the RESPIMAT inhalation solution delivery system

         25. Pregnant or nursing women

         26. Women of childbearing potential not using a highly effective method of birth control.

             Female patients will be considered to be of childbearing potential unless surgically
             sterilised by hysterectomy or bilateral tubal ligation, or post-menopausal for at
             least two years

         27. Patients who have previously been randomized in this study or are currently
             participating in another study

         28. Patients who are unable to comply with pulmonary medication restrictions prior to
             randomization

             At sites performing the shuttle walk tests, patients with the following criteria will
             be excluded from the shuttle walk tests:

         29. Patients who complete level 12 at the incremental shuttle walk test at visit 1a.

         30. Patients with an endurance time >=15 minutes during the training (Visit 2a) or
             baseline (visit 3a) endurance shuttle walk test.